AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02646228 — intervention group
Intervention type: OTHER
Intervention: molecular profiling, patient derived cells
Description: molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer.
Study NCT00221442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: zonegran (zonisamide)
Study NCT00221442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: fake pill
Study NCT02801994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV, Puritan Bennett 980 ventilator
Description: The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
Study NCT03034642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with bilateral bronchoalveolar lavages
Description: Bronchoscopy with bilateral bronchoalveolar lavages
Study NCT01262287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
Study NCT01262287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules in same number as active drug, daily for 8-week treatment period
Study NCT03721263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Single Dose
Study NCT00441129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed paradigm Real Time Sytem
Description: Minimed paradigm Real Time Sytem
Study NCT00441129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimed Paradigm 512/712 Insulin pump
Description: Minimed Paradigm 512/712 Insulin pump
Study NCT04339101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given via infusion
Study NCT04339101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib Adipate
Description: Given PO
Study NCT04339101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04339101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03457753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole Oral Soluble Film
Description: Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
Study NCT01092338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vit D3)
Description: To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
Study NCT02597400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: * Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals
Study NCT02597400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: * Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals.
Study NCT00109291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00109291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study NCT03786731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
Study NCT02351804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + dexamethasone
Description: Adductor canal block, single bolus
Study NCT02351804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine + placebo
Description: Adductor canal block, single bolus
Study NCT03545867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated control (CON)
Description: Seated rest
Study NCT03545867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous (MICT)
Description: Arm cycling at a continuous power output
Study NCT03545867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Arm cycling at power outputs that vary between high and low intensity intervals
Study NCT03545867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT)
Description: Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
Study NCT03545867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Meal
Description: A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
Study NCT00372281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cliavist
Description: Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Study NCT03317002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Oral dose of AZD5718 (tablet)
Study NCT03317002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (tablet)
Study NCT01602887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-0332991
Description: isethionate hard capsule, 125 mg, single dose
Study NCT01602887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: freebase hard capsule with a small particle size, 125 mg, single dose
Study NCT01602887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: freebase hard capsule with a large particle size, 125 mg, single dose
Study NCT01602887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: oral solution, 50 mg, single dose
Study NCT04339101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04339101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT03692533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemistry
Description: Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case.
Study NCT03263429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutaminase Inhibitor CB-839
Description: Given by mouth
Study NCT03263429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given by vein
Study NCT03263429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride (phase I only)
Description: Given by vein
Study NCT03263429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03263429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03263429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans
Description: During phase II at baseline and day 28 of cycle 1
Study NCT02392013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Modification
Description: Removal of home barriers or hazards.
Study NCT00436657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHPP of Cisplatin
Description: Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
Study NCT00436657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery
Description: Surgical removal of abdominal tumors.
Study NCT03783182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason Sodium Phosphate
Description: Glucocorticoid
Study NCT03783182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% glucose solution
Description: Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
Study NCT03556111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sticky bone augmentation
Description: 1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement
Study NCT02219048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 680 micrograms BID, Orally inhaled placebo for 12 weeks
Study NCT02219048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03715455
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
Study NCT03876834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory training
Description: Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
Study NCT04339101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT00758485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Study NCT00758485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (NaCl)
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Study NCT03596593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPANOM (identifying MSI status from ctDNA)
Description: SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
Study NCT00713440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol
Description: OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days
Study NCT02271256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Intimate Apparel
Description: The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
Study NCT03215836 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy and Nasal Epithelium Brush Sampling
Description: After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
Study NCT05865431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Oxide and Avobenzone
Description: Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
Study NCT01805492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dr. Dean Ornish Program for Reversing Heart Disease
Description: Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (\<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
Study NCT03528070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Subjects will be treated with tranilast
Study NCT04227015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA101
Description: CTA101 UCAR-T cell injection by intravenous infusion
Study NCT04940429 — intervention group
Intervention type: DEVICE
Intervention: Neurofit
Description: This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
Study NCT04940429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychometric hepatic encephalopathy score
Description: During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
Study NCT01426165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 8 grams over 4 or 8 hours depending on randomization
Study NCT01982357 — intervention group
Intervention type: DEVICE
Intervention: Laser Speckle Imaging and Diffuse Optical Spectroscopy
Description: Laser Speckle Imaging and Diffuse Optical Spectroscopy
Study NCT01981564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Express Intervention
Description: Asthma Express clinic visit for asthma education + nurse home visit
Study NCT01981564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Education Control Group
Description: Asthma Express home nurse visits for asthma education
Study NCT04531852 — intervention group
Intervention type: OTHER
Intervention: CALSTI - Complex Active Lifestyle Intervention
Description: A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance).
Study NCT04531852 — intervention group
Intervention type: BEHAVIORAL
Intervention: SEMAI - Self-Management Intervention
Description: A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
Study NCT01309633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5mg sunitinib with Cisplatin and Gemcitabine
Description: 1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
Study NCT04777045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride
Description: Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm.
Study NCT04777045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 100mg
Description: 1 x 100 mg PH100 oral capsule
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 200mg
Description: 1 x 200 mg PH100 oral capsule
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 400mg
Description: 2 x 200 mg PH100 oral capsules
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 800mg
Description: 4 x 200 mg PH100 oral capsules
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 1200mg
Description: 6 x 200 mg PH100 oral capsules
Study NCT04335045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 1600mg
Description: 8 x 200 mg PH100 oral capsules
Study NCT03404570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine HCl
Description: Investigational drug
Study NCT03404570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet containing no active drug.
Study NCT04307004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unattended blood pressure measurement
Description: Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
Study NCT04307004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attended blood pressure measurement
Description: Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
Study NCT04307004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory blood pressure monitoring
Description: Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.